Immunotherapy and Radiotherapy: From Diagnosis to Prognosis
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 88
Special Issue Editors
Interests: breast cancer; association of systemic therapy and radiation therapy; central nervous system
Interests: cancer; radiation therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Radiotherapy (RT) plays a vital role in both the curative and palliative treatment of most types of cancer. It has been estimated that more than 50% of patients with cancer will receive radiotherapy as part of cancer care. Among the newer agents widely used in recent years, immunotherapy agents, especially immune checkpoint inhibitors (ICIs), have transformed the prognosis of many advanced malignant tumors.
RT is delivered for purposes of local control, but can also show a systemic effect on remote and non-irradiated tumor sites, which is called abscopal effect. Data suggest that the immunological effect may vary according to the irradiated site and the dose per fraction of radiation.
Given the emerging data indicating systemic immune effects of radiation and redundancies in the mechanisms of ICI- and RT, the systemic immune response can be enhanced via their combination and lead to better prognosis for many tumors. At the same time, this combination may also lead to adverse events in some cases. Moreover, the assessment of patterns of response may be tricky in patients undergoing radiation therapy and immunotherapy. The distinction between treatment-related images changes and recurrence may be particularly challenging with the use of conventional imaging methods.
The aim of this Special Issue of Diagnostics is to highlight research related to the combination of radiotherapy and immunotherapy in terms of diagnosis (treatment-related images changes vs. recurrence), safety profiles, antitumoral activity and prognosis.
We accept clinical or research articles including reviews, original articles and case reports.
Dr. Gokoulakrichenane Loganadane
Dr. Nam P. Nguyen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiotherapy
- immunology
- cancer
- tumor
- diagnosis
- management
- prognosis
